Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)
This is a randomized drug study that will examine if there is a difference between a daily oral LUM- 201 (study drug) and the standard of care drug, Norditropin, over a 24 month period in children, who have not received treatment for Growth Hormone Deficiency (GHD)
Have an established diagnosis of PGHD. Eligible subjects must be naïve-to-treatment and be prepubertal. At Screening, be age ≥ 3.0 years and age < 10.0 years for girls and < 11.0 years for boys Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to Day 1.
Exclusion Criteria:
A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and/or use of medication to treat ADHD Evidence or history of an intracranial mass